Observational studyJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2015
Increasing nontuberculous mycobacteria infection in cystic fibrosis.
Observational study in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 135 citations in OpenAlex.
- Nontuberculous Mycobacteria in Primary Ciliary Dyskinesia: A National Multicenter Cohort Study.Respiration; international review of thoracic diseases · 2026Article
- The Epidemiology of Nontuberculous Mycobacteria in Cystic Fibrosis.Children (Basel, Switzerland) · 2025Review
- The Association ofJournal of clinical medicine · 2025Article
- Epidemiology, microbiology and clinical impacts of non-tuberculous mycobacteria in adult patients with cystic fibrosis.Heliyon · 2025Article
- Molecular mechanism analysis of nontuberculous mycobacteria infection in patients with cystic fibrosis.Future microbiology · 2024Article
- Sources, transmission and hospital-associated outbreaks of nontuberculous mycobacteria: a review.Future microbiology · 2024Review
- Article
- Phylogenomics of nontuberculous mycobacteria respiratory infections in people with cystic fibrosis.Paediatric respiratory reviews · 2023Review
- Simultaneous detection and differentiation ofIranian journal of microbiology · 2023Article
- Identification of Significant Pathogenic Nontuberculous Mycobacteria Species from Presumptive TB Patients Using PartialInfection and drug resistance · 2023Article
- Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Amikacin Liposomal Inhalation Suspension in the Treatment ofOpen forum infectious diseases · 2022Article
- Sputum Metabolites Associated with Nontuberculous Mycobacterial Infection in Cystic Fibrosis.mSphere · 2022Article
- CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.JCI insight · 2022Article
- InJournal of bacteriology · 2022Article
- Development of Inhibitors of SAICAR Synthetase (PurC) fromACS infectious diseases · 2022Article
- Structural Characterization ofFrontiers in molecular biosciences · 2022Article
- Virulence Mechanisms ofFrontiers in microbiology · 2022Review
- Mucosal Immunity in Cystic Fibrosis.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Genome reorganization during emergence of host-associatedMicrobial genomics · 2021Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNontuberculous mycobacteria (NTM) are emerging infections in the CF population.
aimsTo assess NTM infection prevalence and associated features in our CF clinic population.
methodsPatient records, 2002-2011, were reviewed for NTM infection. FEV1, pancreatic function, sputum microbiology, and serum cytokines were compared in patients with and without NTM infection.
resultsIncidence rate of NTM infection increased from 0 in 2002 to 8.7% in 2011 (p<0.001). NTM infection prevalence increased 3-fold from 5% (4/79) in 2003 to 14.5% (16/110) in 2011 (p=0.05). Prevalence of chronic NTM lung disease has decreased somewhat since a peak in 2009, with institution of aggressive triple therapy. Of NTM-infected compared to uninfected patients, 88.2% vs. 60.3% had a known 'severe' CFTR genotype (p=0.04), 88.2% vs. 58.9% were pancreatic insufficient (p=0.02); 70.6% vs. 43.8% had chronic Pseudomonas aeruginosa (p=0.06); 75% vs. 32% had Aspergillus infection (p=0.007) and 23.5% vs 2.7% had allergic bronchopulmonary aspergillosis (p=0.01). Patients infected with Mycobacterium abscessus had increased TGF-β, TNF-α, IL-1β, IL-2, IL-4 and IL-5 levels (p<0.05). There was no difference in cytokine levels for all NTM infected compared to uninfected patients. M. abscessus comprised 46% of all NTM infections. Comparing M. abscessus versus other NTM, duration was 10.5 (1-118) months versus 1 (1-70) month, median (range) (p=0.004); lung disease occurred in 69% versus 17% (p=0.0004), with sputum conversion in 4/11 versus 5/6, respectively (NS).
conclusionsNTM incidence and prevalence have increased dramatically in our CF clinic, associated with a severe CF genotype and phenotype. M. abscessus, the most prevalent NTM, caused prolonged infection despite therapy. There has been some decrease in the prevalence of NTM lung disease since 2009.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.